Chennai: Bharat Biotech has completed enrollment of 25,800 volunteers for the Phase-3 trials of its Covid-19 vaccine Covaxin, Suchitra Ella, joint managing director, Bharat Biotech International Ltd said on Thursday.
In a message posted on the company’s Twitter account, she thanked clinical trial sites, principal investigators and health workers for their support and trust in the āpublic- private partnershipā vaccine discovery.
“My deep appreciation to all the volunteers for reposing and expressing Pro Vaccine Public Health Voluntarism in the phase-3 clinical trials of India”s 1st fully indigenous Covid-19 vaccine,” she said referring to Covaxin.
The Drug Controller General of India (DCGI) has recently given Emergency Use Authorisation for Covaxin.
The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers across India.
The company had said it is the only Phase-3 efficacy study for a Covid-19 vaccine, and the largest efficacy trial (Phase-3) ever conducted for any vaccine in India
Meanwhile, the Union health ministry has informed States and Union Territories that they are likely to receive the first supply of Covid-19 vaccine shortly and asked them to remain prepared to accept these consignments.
In a communique, the Ministry said vaccine will be supplied to the identified consignee points of 19 States and union territories — Andhra Pradesh, Assam, Bihar, Chhattisgarh, Delhi, Gujarat, Haryana, Jharkhand, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Odisha, Punjab, Rajasthan, Tamilnadu, Telangana, Uttar Pradesh and West Bengal, by the supplier.
The vaccine for remaining 18 states and Union Territories, Andaman and Nicobar Islands, Arunachal Pradesh, Chandigarh, Daman and Nagar Haveli, Daman and Diu, Goa, Himachal Pradesh, Jammu and Kashmir, Ladakh, Lakshadweep, Manipur, Meghalaya, Mizoram, Nagaland, Puducherry, Sikkim, Tripura and Uttarakhand, will be received from their respective government medical store depots.